Nap B.V. Forgrowth Sells 25,132 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 25,132 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $25.49, for a total transaction of $640,614.68. Following the transaction, the insider now directly owns 10,777,092 shares in the company, valued at $274,708,075.08. The trade was a 0.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.60, for a total value of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.10, for a total value of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total value of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Trading Up 1.1 %

NAMS stock traded up $0.28 during trading hours on Thursday, hitting $26.23. 354,642 shares of the stock traded hands, compared to its average volume of 377,634. The stock has a 50-day simple moving average of $21.72 and a 200 day simple moving average of $19.09. NewAmsterdam Pharma has a one year low of $10.50 and a one year high of $27.29.

Wall Street Analysts Forecast Growth

NAMS has been the subject of a number of analyst reports. Needham & Company LLC restated a "buy" rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Piper Sandler reiterated an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Scotiabank raised their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $36.20.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Banque Cantonale Vaudoise bought a new stake in shares of NewAmsterdam Pharma in the 2nd quarter worth approximately $38,000. Quarry LP increased its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after buying an additional 6,247 shares in the last quarter. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares during the last quarter. Bellevue Group AG bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth $128,000. Finally, XTX Topco Ltd acquired a new position in shares of NewAmsterdam Pharma in the 3rd quarter worth $187,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.